Episurf Medical AB (OSTO:EPIS B) OCF Margin %: 383.33% (As of Mar. 2026)


What is Episurf Medical AB OCF Margin %?

Episurf Medical AB OSTO:EPIS B +0.65% OCF Margin % is 383.33% as of Mar. 2026. The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Episurf Medical AB ranks worse than 89.45% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Episurf Medical AB's Cash Flow from Operations for the three months ended in Mar. 2026 was kr11.50 Mil. Episurf Medical AB's Revenue for the three months ended in Mar. 2026 was kr3.00 Mil. Therefore, Episurf Medical AB's OCF Margin % for the quarter that ended in Mar. 2026 was 383.33%.

As of today, Episurf Medical AB's current OCF Yield % is -4.49%.

The historical rank and industry rank for Episurf Medical AB's OCF Margin % or its related term are showing as below:

OSTO:EPIS B' s OCF Margin % Range Over the Past 10 Years
Min: -2456   Med: -1067.52   Max: -409.63
Current: -228.57

During the past 13 years, the highest OCF Margin % of Episurf Medical AB was -409.63%. The lowest was -2456.00%. And the median was -1067.52%.

OSTO:EPIS B's OCF Margin % is ranked worse than
89.45% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 5.86 vs OSTO:EPIS B: -228.57

Episurf Medical AB OCF Margin % Related Terms

Episurf Medical AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Episurf Medical AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Episurf Medical AB OCF Margin % Chart

Episurf Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -918.46 -1,053.03 -823.30 -549.23 -409.63

Episurf Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -503.45 -437.50 -334.29 383.33

OSTO:EPIS B vs ABT, SYK, MDT: OCF Margin % Comparison

For the Medical Devices subindustry, Episurf Medical AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Episurf Medical AB OCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Episurf Medical AB's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Episurf Medical AB's OCF Margin % falls into.


Episurf Medical AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Episurf Medical AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-55.3/13.5
=-409.63 %

Episurf Medical AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=11.5/3
=383.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 383.33% mean?
Episurf Medical AB (OSTO:EPIS B) has a OCF Margin % of 383.33% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Episurf Medical AB and its competitors. According to the industry distribution chart, Episurf Medical AB ranks #729 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 89.4%.
Is Episurf Medical AB's OCF Margin % too high?
Episurf Medical AB's current OCF Margin % is 383.33%. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Episurf Medical AB's value of 383.33% is 6441.5% above this industry median. Based on the distribution chart, Episurf Medical AB ranks #729 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Episurf Medical AB's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Episurf Medical AB ranks #729 out of 815 companies for OCF Margin %. This places Episurf Medical AB in the lower half of its industry. The industry median OCF Margin % is 5.86. Episurf Medical AB's value of 383.33% is 6441.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Episurf Medical AB's current OCF Margin % of 383.33% is 6441.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Episurf Medical AB and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Episurf Medical AB's current OCF Margin % is 383.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Episurf Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Episurf Medical AB (OSTO:EPIS B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.09 — trading 85.2% above its estimated fair value. The current OCF Margin % is 383.33% and 6441.5% above the Medical Devices & Instruments industry median of 5.86. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Episurf Medical AB (OSTO:EPIS B), the current OCF Margin % is 383.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Episurf Medical AB Business Description

Other Exchanges 0QUT:UK16E:Germany
Address Karlavagen 60, Stockholm, SWE, 114 49
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.